Stock News

Ensemble Capital Management Has Boosted Broadridge Finl Solutions In (BR) Position; 12 Analysts Are Bullish Agios Pharmaceuticals, Inc. (AGIO) Last Week

Ensemble Capital Management Llc increased Broadridge Finl Solutions In (BR) stake by 1.99% reported in 2017Q2 SEC filing. Ensemble Capital Management Llc acquired 9,450 shares as Broadridge Finl Solutions In (BR)’s stock rose 6.96%. The Ensemble Capital Management Llc holds 483,788 shares with $36.56M value, up from 474,338 last quarter. Broadridge Finl Solutions In now has $10.44 billion valuation. The stock increased 0.29% or $0.26 during the last trading session, reaching $89.53. About 427,161 shares traded. Broadridge Financial Solutions, Inc. (NYSE:BR) has risen 17.08% since December 10, 2016 and is uptrending. It has outperformed by 0.38% the S&P500.

Among 16 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 12 have Buy rating, 0 Sell and 4 Hold. Therefore 75% are positive. Agios Pharmaceuticals had 41 analyst reports since July 23, 2015 according to SRatingsIntel. On Tuesday, August 1 the stock rating was maintained by Cowen & Co with “Buy”. Leerink Swann downgraded the shares of AGIO in report on Monday, December 7 to “Market Perform” rating. Roth Capital maintained the stock with “Hold” rating in Wednesday, August 5 report. The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has “Outperform” rating given on Wednesday, May 18 by Credit Suisse. The company was maintained on Friday, September 15 by Needham. The firm earned “Outperform” rating on Tuesday, January 17 by Oppenheimer. JP Morgan upgraded Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) on Monday, June 13 to “Overweight” rating. Credit Suisse maintained the shares of AGIO in report on Thursday, November 2 with “Outperform” rating. Canaccord Genuity maintained Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) rating on Friday, August 7. Canaccord Genuity has “Hold” rating and $93 target. The firm earned “Outperform” rating on Wednesday, August 2 by Leerink Swann. See Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) latest ratings:

19/11/2017 Broker: SunTrust Rating: Buy New Target: $80.0 Maintain
01/11/2017 Broker: RBC Capital Markets Rating: Buy New Target: $80.0 Maintain
02/11/2017 Broker: Credit Suisse Rating: Outperform Old Target: $61 New Target: $66 Maintain
03/10/2017 Broker: SunTrust Rating: Buy New Target: $80.0 Maintain
18/09/2017 Broker: J.P. Morgan Rating: Buy New Target: $76.0 Maintain
15/09/2017 Broker: Needham Rating: Buy New Target: $72.0 Maintain
15/09/2017 Broker: RBC Capital Markets Rating: Outperform New Target: $78 Initiates Coverage On
08/08/2017 Broker: SunTrust Rating: Buy New Target: $80.0000
08/08/2017 Broker: Cowen & Co Rating: Buy Maintain
08/08/2017 Broker: Oppenheimer Rating: Buy New Target: $83.0000 Maintain

Investors sentiment decreased to 1.02 in Q2 2017. Its down 0.03, from 1.05 in 2017Q1. It fall, as 33 investors sold BR shares while 155 reduced holdings. 53 funds opened positions while 139 raised stakes. 95.50 million shares or 2.47% less from 97.92 million shares in 2017Q1 were reported. Guggenheim Cap Limited Liability holds 144,661 shares. 32,934 are owned by Hartline Investment. Boyar Asset Mngmt owns 12,700 shares for 0.71% of their portfolio. Aull And Monroe Invest Mngmt Corp invested in 0.13% or 3,164 shares. Schroder Investment Mgmt reported 70,000 shares. Pnc Gru owns 78,938 shares. Pennsylvania-based Susquehanna International Grp Llp has invested 0% in Broadridge Financial Solutions, Inc. (NYSE:BR). Mariner Wealth Advsrs Lc has invested 0.02% in Broadridge Financial Solutions, Inc. (NYSE:BR). Ontario – Canada-based Comml Bank Of Montreal Can has invested 0% in Broadridge Financial Solutions, Inc. (NYSE:BR). Stanley, a Alabama-based fund reported 9,905 shares. Proshare Advisors Limited Liability Company holds 8,752 shares or 0.01% of its portfolio. Brown Advisory Inc owns 1.30M shares for 0.3% of their portfolio. Alliancebernstein Ltd Partnership invested 0.04% in Broadridge Financial Solutions, Inc. (NYSE:BR). Boston Private Wealth Lc holds 172,738 shares or 0.51% of its portfolio. Teachers Retirement Of The State Of Kentucky has invested 0.02% in Broadridge Financial Solutions, Inc. (NYSE:BR).

Among 7 analysts covering Broadridge Financial Solutions (NYSE:BR), 1 have Buy rating, 0 Sell and 6 Hold. Therefore 14% are positive. Broadridge Financial Solutions had 15 analyst reports since August 14, 2015 according to SRatingsIntel. The rating was maintained by Barclays Capital on Monday, November 2 with “Overweight”. The stock of Broadridge Financial Solutions, Inc. (NYSE:BR) earned “Market Outperform” rating by Avondale on Friday, January 8. JP Morgan maintained it with “Neutral” rating and $59 target in Friday, August 14 report. The stock has “Equal-Weight” rating by Barclays Capital on Wednesday, August 10. The stock of Broadridge Financial Solutions, Inc. (NYSE:BR) has “Overweight” rating given on Wednesday, September 16 by Barclays Capital. Atlantic Securities initiated the shares of BR in report on Tuesday, September 13 with “Overweight” rating. The firm earned “Sell” rating on Friday, August 14 by Zacks. The company was downgraded on Wednesday, June 15 by Avondale. Raymond James downgraded Broadridge Financial Solutions, Inc. (NYSE:BR) on Tuesday, June 7 to “Market Perform” rating. On Thursday, September 29 the stock rating was downgraded by Sandler O’Neill to “Hold”.

The stock increased 0.23% or $0.14 during the last trading session, reaching $60.97. About 443,590 shares traded or 17.58% up from the average. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has risen 8.52% since December 10, 2016 and is uptrending. It has underperformed by 8.18% the S&P500.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company has market cap of $2.97 billion. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. It currently has negative earnings. The firm is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients.

Investors sentiment increased to 2.04 in 2017 Q2. Its up 0.71, from 1.33 in 2017Q1. It increased, as 14 investors sold Agios Pharmaceuticals, Inc. shares while 32 reduced holdings. 22 funds opened positions while 72 raised stakes. 44.72 million shares or 14.71% more from 38.98 million shares in 2017Q1 were reported. Tiaa Cref Invest Mgmt reported 0% stake. Moreover, Pnc Svcs Group has 0% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 45 shares. Clearbridge Invs Lc holds 1.53M shares. Grp Incorporated One Trading L P has invested 0.01% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Prelude Management Limited Liability Corp, New York-based fund reported 3,476 shares. Eventide Asset Mngmt Limited Liability Company accumulated 0.96% or 300,800 shares. The Australia-based Platinum Invest Management has invested 0.05% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Bnp Paribas Asset Mngmt Holdg invested in 205,641 shares. Tower Llc (Trc) accumulated 180 shares or 0% of the stock. Qs Lc holds 2,800 shares. Principal Fincl Grp holds 0% or 7,083 shares. 13,575 were reported by Bnp Paribas Arbitrage. Point72 Asia (Hong Kong) Limited reported 395 shares or 0.02% of all its holdings. Ameriprise has invested 0% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Valley Natl Advisers holds 0% of its portfolio in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 157 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *